Today, the Exec. Vice Chairman of Hemispherx Biopharma (HEB), Thomas Equels, bought shares of HEB for $2,278.
This recent transaction increases Thomas Equels’ holding in the company by 1.68% to a total of $138.8K.
See today’s analyst top recommended stocks >>
Currently, Hemispherx Biopharma has an average volume of 552.5K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen.
